Batman and Superman can add another superhero to their ranks at publisher DC Comics, and that's Scott. The teenage protagonist and his trusty sidekick--Turbo the toy dog--feature in the company's latest graphic novel, which Novartis partnered to create for teens with tuberous sclerosis complex.
Novartis has predicted that its launch of newly FDA-approved heart failure med Entresto would be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe.
Mark Fishman, head of Novartis' $10 billion research operation, is retiring next year, making way for an award-winning Harvard oncologist after 13 years at the helm.
Novartis has stood by its commitment to emerging markets even in rocky times. And now, it's furthering that commitment with an access initiative for low-income countries.
Novartis will make its heart failure drug Entresto at a Singapore site starting this year, CEO Joe Jimenez told the Straits Times newspaper, adding that plans are also underway to expand contact lens manufacturing in the city-state.
China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on keeping on, says Novartis CEO Joe Jimenez.
Two weeks ago, Novartis launched a copy of Amgen's Neupogen (filgrastim), its first in what it expects to be a thriving business in biosimilars, in the U.S. In anticipation of big sales, its Sandoz unit has now opened a plant in Austria to make the autoinjectors that will dispense the drugs.
The U.S. may be getting its first adjuvanted flu vaccine. On Tuesday, an FDA panel recommended accelerated approval of Novartis' Fluad--now owned by CSL's flu vaccine subsidiary--in individuals 65 and older.
Novartis has been talking up the potential of its brand-new heart failure therapy, Entresto, noting that it could be the company's biggest launch ever. And consumers are taking note.
The internet is buzzing with anticipation over Novartis' heart failure treatment Entresto. The promising treatment, fast-track approved by the FDA in early July, saw a 1,400% increase in consumer conversation since then, according to healthcare insights company Treato.